Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. by Trotter, M. J. et al.
Br. J. Cancer (1990), 62, 903-908 © Macmillan Press Ltd.,
Effect of vascular marker Hoechst 33342 on tumour perfusion and
cardiovascular function in the mouse
M.J. Trotter, P.L. Olive & D.J. Chaplin
Medical Biophysics Unit, BC Cancer Research Centre, 601 West 10th Avenue, Vancouver, BC, Canada V5Z IL3.
Summary The fluorescent stain Hoechst 33342 (H33342) has been employed extensively as an in vivo marker
of functional tumour vasculature. We have found that H33342 causes a transient, dose-dependent decrease in
tumour red blood cell (RBC) flow in SCCVII tumours as measured using laser Doppler flowmetry. After
intravenous bolus injection of 15 mg kg-' to anaesthetised mice, blood flow in subcutaneous back tumours
declined to 19 ± 11% of pretreatment values, returning to normal in <7 min. The effect was less pronounced
in mice bearing foot tumours in which flow decreased to 52± 14% of pretreatment values in unanaesthetised
mice and to 50 ± 15% in anaesthetised animals. RBC flow in foot tumours remained significantly depressed for
only 2-3 min. A dose of 5 mg kg-' was not significantly vasoactive in back tumours. H33342 also caused a
transient 20±6 mmHg decline in mouse arterial blood pressure. Blood pH and haematocrit, and tumour cell
oxygen consumption were unchanged by H33342. H33342-induced flow changes did not affect results obtained
using an in vivo double staining protocol provided that the interval between stain injections was >5 min. Due
to its transient effects on tumour perfusion, the stain caused radiobiological tumour hypoxia if injected
immediately prior to X-irradiation. Injection 20 min before irradiation had no influence on tumour radiation
response. We conclude that the transient nature of H33342-induced perturbations in mouse cardiovascular
physiology and tumour blood flow must always be considered but do not preclude the use of the stain as a
vascular marker to detect spontaneous tumour blood flow fluctuations or acute hypoxia.
The bisbenzamide compound Hoechst 33342 (H33342) is a
DNA-binding fluorescent stain used extensively in flow
cytometry studies to quantify DNA content in live cells
(Arndt-Jovin & Jovin, 1977) and to select cells from different
locations within multicell spheroids (Durand, 1982) and ex-
perimental solid tumours (Chaplin et al., 1985, 1986, 1987;
Loeffler et al., 1987; Siemann & Keng, 1988; Young & Hill,
1989; Durand et al., 1990). Perivascular tumour cells avidly
bind intravenously injected H33342 and are therefore more
brightly fluorescent than cells distant from the blood supply
which are exposed to lower dye concentrations. Thus,
H33342 acts as a marker of perfused tumour vasculature
(Reinhold & Visser, 1983) and can be used to quantify
vascular morphology (Smith et al., 1988; Fallowfield, 1989).
The stain has also been employed in double-labelling techni-
ques to identify tumour vessels subject to transient nonper-
fusion (Chaplin et al., 1987; Jirtle, 1988; Trotter et al., 1989a)
and to isolate tumour cells which are made acutely hypoxic
by these flow fluctuations (Chaplin et al., 1986, 1987; Min-
chinton et al., 1990). Hoechst-staining methods have also
been used to examine the effects of vasoactive drugs (Trotter
et al., 1989c) and chemotherapeutic agents (Murray et al.,
1987; Zwi et al., 1989) on functional tumour vasculature.
Ideally, vascular markers for use in vivo should have no
significant influence on metabolic or physiologic processes.
H33342 has been shown to cause DNA damage, cell cycle
perturbations, and radioprotection in vitro (Durand & Olive,
1982; Smith & Anderson, 1984; Young & Hill, 1989) but
these effects generally occur at concentrations much higher
than those achievable in vivo. However, decreased tumour
perfusion has been observed in some experimental tumours
following H33342 administration (Smith et al., 1988; Zwi et
al., 1989). To date, all direct histological and radiobiological
evidence for transient perfusion and acute hypoxia in rodent
tumours is based on experiments which utilise H33342 stain-
ing of tumour perivascular cells. Thus, any influence of
H33342 on tumour physiology must be understood before
results of experiments employing the stain can be definitively
interpreted.
The purpose of this study was to measure the effect of
H33342 on mouse cardiovascular and metabolic parameters
and the influence of the stain on blood flow and radiation
response of murine SCCVII carcinoma. The time course of
vasoactive effects, if they occur, is of critical importance since
a short-lived, reversible change in tumour blood flow is not
necessarily a contraindication to the use of H33342 for detec-
tion of intermittent tumour perfusion and acute hypoxia
using histologic or radiobiologic techniques.
Materials and methods
Mice and tumours
Experiments were performed using murine SCCVII carcin-
oma, a rapidly growing, poorly differentiated squamous cell
carcinoma, implanted subcutaneously (s.c.) as a single cell
suspension in 6-8-week-old male C3H/He mice. Details of
the origin and maintenance of this tumour has been pub-
lished previously (Olive et al., 1985). For laser Doppler
measurements of tumour blood flow, tumours implanted s.c.
over the sacral region (tumour size 50-1,000 mg) or s.c. in
the hindfoot dorsum (tumour size 50-250 mg) were used. In
double fluorescent staining experiments and in measurement
of tumour radiation response, SCCVII tumours implanted
s.c. over the sacral region were used.
Fluorescent stains
Hoechst 33342 (Sigma, St Louis, MO, USA) was dissolved in
phosphate buffered saline (PBS) and administered intra-
venously via the lateral tail vein at doses of 5-30 mg kg-' in
an injection volume of 50 1tl. The fluorescent vascular marker
DiOC7(3) (Olive & Durand, 1987; Trotter et al., 1989b)
(Molecular Probes Inc., Eugene, OR, USA) was dissolved in
dimethylsulphoxide (DMSO) and diluted to 75% DMSO
with PBS prior to intravenous injection. The stain was
injected at a dose of 1 mg kg-' in 50Ild. DiOC7(3) has known
vasoactive effects, and therefore in some experiments, fluores-
cent zinc cadmium sulphide particles (1-10 lim in size; 30 mg
ml-', 100 il injection volume; Duke Scientific, Palo Alto,
CA, USA) were substituted for DiOC7(3) as the second
vascular marker in a double staining protocol (Chaplin et al.,
1987).
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Tumour andnormal tissue bloodflow
Blood flow in tumour tissue and in normal skin was
measured using laser Doppler flowmetry (Haumschild, 1986;
Shepherd et al., 1987). Details of the experimental method
have been published previously (Trotter et al., 1989b,c). The
technique allows dynamic measurement of relative red blood
cell (RBC) flow in small (approximately 1 mm3) tissue
volumes, and is ideally suited to detect rapid onset, transient
flow changes. Laser Doppler measurements are very sensitive
to motion artifact and for flow determinations in s.c. back
tumours, mice were immobilised with ketamine (45mgkg-'
i.p.) and diazepam (10 mg kg-' i.p.). A 1-2 mm incision was
made in the skin directly overlying the tumour and a 0.7 mm
diameter needle probe was placed through this incision onto
the tumour surface. For tumours implanted in the foot, mice
were restrained in a box jig with the tumour-bearing foot
immobilised with tape. The Doppler probe was placed direct-
ly on the thinned skin over the tumour; no skin incision was
made. The effect of H33342 on RBC flow in foot tumours
was measured in both anaesthetised and unanaesthetised
mice. Blood flow measurements in normal tissue were made
in skin on the dorsum of the foot (non-tumour-bearing). In
all blood flow experiments, H33342 was administered via an
indwelling catheter placed in the lateral tail vein.
Cardiovascular parameters
Measurements of arterial blood pressure and heart rate were
made in the male C3H/He mice anaesthetised with halothane,
administered continuously, via vapouriser, at a concentration
of 0.5-2.5% in pure oxygen. Mice were allowed to breathe
spontaneously. Temperature was maintained at 35-37°C
using a heating pad. The left femoral artery was catheterised
using saline-filled PEIO tubing (o.d. 0.61 mm). Pressure
measurements were recorded using a Statham P23D pressure
transducer (Gould, Oxnard, CA, USA) connected to an
amplifier and recorder (General Electric Co., Liverpool, NY,
USA). Heart rate could be read directly from the arterial
pressure waveform. Prior to intravenous injection of H33342,
mean arterial blood pressure was titrated to a baseline level
of 80-90 mmHg by adjusting the concentration of inhaled
halothane.
Metabolic parameters
The effect of H33342 (0-400ytg ml-') on relative oxygen
utilisation of disaggregated SCCVII tumour cells was
measured in vitro using the method described by Biaglow and
Durand (1976). The decrease in dissolved oxygen concen-
tration in a stirred cell suspension (5.0 x 10 cells ml-') held
at 37°C was measured in a closed reaction vessel with a
Clark-type oxygen electrode (Yellow Springs Instrument Co.,
Yellow Springs, OH, USA).
Measurements of blood P02, CO2, pH, haematocrit, and
haemoglobin saturation were made before and after injection
of H33342 (15 mg kg-'). Orbital sinus blood samples were
collected in microhaematocrit tubes and blood was analysed
using an automated blood gas analyser (ABL300) connected
via a serial interface to an oximeter (OSM3) for measurement
of haemoglobin saturation (Radiometer, Copenhagen, Den-
mark). The required sample volume was 35 ,ll and all
measurements were performed at 37°C.
Doublefluorescent labelling technique
An in vivo double-labelling method, designed to identify
regions of transient tumour perfusion, has been described in
detail previously (Trotter et al., 1989a). Sequential i.v. injec-
tion of two fluorescent vascular markers (H33342 and the
carbocyanine dye DiOC7(3)) allows detection, in tumour
frozen sections, of vessels with unmatched staining resulting
from transient vessel nonperfusion. Blood vessels stained
only with H33342 (injected first) are said to have 'closed'
during the interval between stain injections. Conversely,
vessels outlined only by DiOC7(3) (injected second) have
'opened'. Use of this terminology does not imply that col-
lapse of the vessel lumen is responsible for staining mis-
match, only that the vessel was temporarily non-perfused.
Double-labelling experiments were performed in s.c. SCCVII
tumours and the interval between stain injections was varied
from 5 to 60 min. H33342 was injected at a dose of 15 mg
kg-' and DiOC7(3) at a dose of 1 mg kg-1. Mice were killed
5 min after DiOC7(3) injection. In some experiments, fluores-
cent zinc cadmium sulphide particles were injected in place of
DiOC7(3).
Radiation response
To determine if H33342 influenced tumour oxygenation and
thus the tumour response to radiation, the stain was
administered at varying intervals before and after an X-ray
dose of 10 Gy. SCCVII tumours in unanaesthetised, restrain-
ed mice were locally irradiated, using parallel opposed fields,
at a dose rate of 3.16 Gymin-' using a 250 kVp X-ray
source. H33342 was given i.v. in 50flI volume 20 min before,
immediately before, or 20 min after irradiation. Some mice
were killed 5 min after H33342 injection and the tumours
then irradiated to obtain the response of a completely anoxic
cell population. Following treatment, tumours were excised
and enzymatically dissociated to a single cell suspension as
described previously (Olive et al., 1985). Cells were then
incubated for 1-2 min with fluorescein isothiocyanate
(FITC)-labelled anti-mouse IgG (whole molecule; Sigma) to
stain non-tumour host cells, predominantly macrophages
(Olive, 1989). Cells were anlaysed using fluorescence-
activated cell sorting (FACS 440, Becton-Dickinson, Sun-
nyvale, CA, USA): equal numbers of FITC-negative (i.e.
tumour) cells were sorted into 10 fractions based on cellular
H33342 concentration. The clonogenicity of each fraction
was assessed by plating cells, counted by the cell sorter, into
100 mm plastic cell culture plates and incubating in 5% 02,
5% CO2, and 90% N2 at 37°C for 10 days. Colonies were
then stained with malachite green and counted.
Results
Tumour bloodflow
H33342 caused a dose-dependent reduction in tumour red
blood cell (RBC) flow in the SCCVII carcinoma as measured
by laser Doppler flowmetry (Figures 1 and 2). In immobilised
mice (ketamine/diazepam anaesthesia) bearing subcutaneous
back tumours, an H33342 dose of 15 mgkg-' reduced RBC
flow to 19 ± 11% of normal with a return to pretreatment
flow in <7 min (Figure 1). In foot tumours, the decline in
RBC flow was less pronounced in both anaesthetised
(50 ± 15% of normal) and unanaesthetised mice (52 ± 14%
of normal). In foot tumours, RBC flow was significantly
different from pretreatment values for only 2-3 min post-
injection. A dose of 5 mg kg' was not significantly vaso-
active (Figure 2). No long-term reductions in flow were
observed using this method. In back tumours, the number of
moving RBCs (indicative of functional microvascular
volume) also declined following H33342 administration
(15 mgkg-') (59% of normal, P<0.001) but this effect was
much less pronounced in foot tumours (74% and 89% of
normal with and without anaesthesia respectively, P<0.05).
Most of the tumour blood flow reduction induced by H33342
was a result of a decrease in mean RBC velocity: in back
tumours RBC velocity declined to 31% of pretreatment
values while in foot tumours velocity decreased to 62% in
anaesthetised mice and to 58% in unanaesthetised mice
(P<0.001). Blood flow reduction was observed in tumours
ranging in size from 50 to 1,000 mg. Flow reduction in large
back tumours> 800 mg was not significantly different than
that of small tumours <200 mg (19 ± 12% of pretreatment
values vs 21 ± 7%). H33342 had no significant effect on
blood flow in skin of a non-tumour-bearing foot.HOECHST 33342 AND TUMOUR PERFUSION 905
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Figure 1 Effect of H33342 (15mgkg-' i.v.) on red blood cell
(RBC) flow, number of moving RBCs (indicative of functional
microvascular volume), and mean RBC velocity as assessed by
laser Doppler flowmetry. SCCVII tumours were either implanted
subcutaneously over the sacral region and mice immobilised with
ketamine/diazepam anaesthesia (e) (n = 8) or tumours were
implanted subcutaneously in the hindfoot dorsum: (0) anaes-
thesia (n = 5), (0) no anaesthesia (n = 6). Error bars represent
s.e.m. In back tumours, RBC flow, from 1 to 6 min inclusive, is
significantly different (P<0.05) than pretreatment values. In foot
tumours, RBC flow is only significantly different (P<0.05) than
pretreatment values at 1 and 2 min post-H33342 injection.
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Figure 2 Effect of i.v. H33342 dose on tumour RBC flow.
Measurements were made in SCCVII tumours implanted sub-
cutaneously over the sacral region. Mice were immobilised with
ketamine/diazepam anaesthesia. 0, Maximum reduction in RBC
flow. 0, Duration of flow reduction, i.e. time to return to
pretreatment values. Error bars represent s.d.
The tumour blood flow reduction observed following
H33342 injection is unlikely to be an artifact of the measure-
ment technique since the absorption spectrum of H33342
does not overlap with that ofthe infrared laser (780 ± 20 nm)
and the stain did not alter the laser Doppler DC voltage
signal, i.e. H33342 staining did not affect the amount of light
scattered by stationary tumour cells (data not shown).
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Figure 3 Effect of H33342 (15mgkg' i.v. in 50ul injection
volume) on mean arterial blood pressure (MABP) (0) and heart
rate (HR) (0) in 8-week-old male C3H/He mice (n = 5) anaes-
thetised with halothane via vapouriser. Error bars represent s.d.
The maximum decline in blood pressure was 20±6mmHg (range
11-26mmHg) which is statistically significant (P<0.005). No
significant change in heart rate was observed.
Bloodpressure/heart rate
H33342 caused a transient reduction in mean arterial blood
pressure measured directly in anaesthetised C3H/He mice
(Figure 3). Blood pressure declined following i.v. H33342
injection in all five animals tested. Pretreatment blood pres-
sure was 86±4 mmHg. The minimum pressure recorded
after H33342 injection was 66-± 9 mmHg and thus the max-
imum decrease in blood pressure was 20± 6mmHg (range
11-26 mmHg; P<0.005). Blood pressure remained signi-
ficantly lower than pretreatment values up to 23 min after
H33342 injection (P<0.05), although a return to near base-
line levels occurred by 14 min. Heart rate was not signi-
ficantly changed.
Metabolic parameters
H33342 at concentrations as high as 400gxg ml-' had no
significant effect on oxygen utilisation by SCCVII cells in
vitro. A concentration of 400 Lgml1' would be expected to
produce tumour intracellular H33342 concentrations at least
100 x those achievable in vivo (Olive et al., 1985). Oxygen
consumption (relative to untreated cells) was 0.99 ± 0.07
(n = 6) and 0.92 ± 0.08 (n = 10) for H33342 concentrations
of 100pgml ' and 400figml-' respectively. Venous blood
pH, PO2, and pCO2 were not significantly altered following
H33342 administration (Table I). A slight drop in systemic
haematocrit was noted but this was also seen in control
animals and was likely the result of repeated orbital sinus
blood sampling. No effect on the oxygen-haemoglobin dis-
sociation curve was observed. H33342 had no effect on rectal
skin, or tumour temperature (data not shown).
Transient tumourperfusion
In a previous report (Trotter et al., 1989a), when H33342 and
DiOC7(3) injections were separated by a 20 min interval,
8.9 ± 2.4% of vessels in 500 mg s.c. SCCVII tumours exhib-
ited staining mismatch indicative of transient perfusion.
Small tumours (4 100 mg) did not show significant levels of
staining mismatch.
To further validate the use of H33342 as the first vascular
marker in a double staining regimen, the interval between
stain injections was varied between 5 and 60min. If H33342-
induced transient reductions in tumour perfusion affect the
staining mismatch levels obtained then mismatch should de-
cline with increasing injection interval. In addition, vessel
closing would presumably predominate relative to vessel
opening. No significant difference in mismatch levels was
noted for injection intervals of 15 to 60min (Table II). For
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all intervals, the overall mismatch was significantly greater
than when stains were injected simultaneously (P<0.01).
The overall staining mismatch observed using a 20 min inter-
val in this series of experiments (performed as a group over a
2-month period) was 5.4+ 1.8% (n = 15, tumour weight
560 ± 210 mg) a value less than the 8.9 ± 2.4% found in
earlier similar experiments (Trotter et al., 1989a). Similar
tumour transplant generations were used and we have no
explanation for the slightly reduced level of staining mis-
match observed in the present study.
An injection interval of 5 min resulted in a highly variable,
artifactually elevated staining mismatch (11.8 ± 11.7%) with
a disproportionate amount of vessel closure (H33342, no
DiOC7(3)) (Figure 4) due to the vasoactive effect of H33342.
Apart from this 5 min injection interval, no significant in-
crease in vessel closing relative to vessel opening was
observed.
If fluorescent particles were used in place of DiOC7(3)
(Chaplin et al., 1987; Jirtle, 1988) then vessels marked with
intraluminal particles and not H33342 represented those that
opened in the interval between injections. In SCCVII
tumours, 6.4% of vessels were found to have opened using
this method (data not shown), demonstrating that DiOC7(3)
itself is not responsible for reperfusion of previously nonper-
fused vessels.
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Figure 4 Effect of the interval between stain injections on vessel
'opening' ( ^) and vessel 'closing' (_) in SCCVII carcinoma
implanted subcutaneously in the back. Values are expressed as a
percent (±+s.em., n = 7-15S) of all mismatched vessels. Differences
between the amount of vessel opening and the amount of closing
are not statistically significant with the exception of interval=
5mmn where closing (10.7±+11.9%, mean±+s.d.) exceeded opening
(1.05+±0.71%, mean±s.d.) (P<0.025) due to the transient effects
of H33342 on tumour blood flow.
Radiation response
The overall radiation response of SCCVII tumour cells
depended on the time of H33342 injection relative to radia-
tion treatment. H33342 injection 20 min before or 20 min
after irradiation resulted in essentially identical tumour cell
survival in all sort fractions (Figure 5). If, however, tumours
were irradiated during the period of reduced tumour blood
flow following H33342 injection, i.e. administration of
H33342 immediately prior to irradiation, the cell survival was
elevated compared to the survival observed when H33342
injection and radiation were separated by 20 min although
this increase is only statistically significant (P<0.01) in
Tablet Effect ofH33342 (15 mg kg-'i.v.) on venous blood gases,pH,
oxyhaemoglobin saturation (HBO2), and haematocrit (HCt) in
unanaesthetised C3H/He mice
Pretreatment 5 minutes 20 minutes
pH 7.33±0.01 7.33±0.01 7.27±0.07
pCO2 (mmHg) 44±3 37±2 41±3
p02 (mmHg) 34±2 35±3 34±5
HBO2(%) 38±3 40±5 38± 10
HCt (%) 46±2 42±1 40±1
(no drug)
HCt (%) 46±2 43±1 42±3
(H33342)
Parameters were measured prior to, 5 min after, and 20 min after
H33342 injection. Means±s.d. for 5-7 mice are shown.
Table II Effect of the interval between stain injections (INT) on
prefusion mismatch in SCCVII carcinoma implanted subcutaneously in
the back
INT Weight Open Closed Total
(min) n (mg) (%) (%) (%)
0 11 0.70±0.53 0.98±0.37 0.34±0.38 1.34±0.50
5 8 0.50±0.11 1.05±0.71 10.7± ll.9b 11.8± 11.7b
10 7 0.51±0.07 1.70±0.66b 1.06±0.72b 2.75± 1.04b
15 9 0.66±0.11 3.43±2.53b 2.28±2.84a 5.72± 3.28c
20 15 0.56±0.21 2.72±1.39c 2.71 ± 1.97c 5.41 ± 1.77c
30 8 0.70±0.22 3.05±1.60c 1.95±1.24c 5.00± 1.94c
45 8 0.74±0.23 3.20±2.80a 3.26±2.21c 6.48±3.05c
60 9 0.60±0.17 1.74± 1.35 3.33±2.72b 5.04±2.74c
The percentage oftotal vessels exhibiting stianing mismatch is shown
(mean±s.d.); thisvalueisfurthersubdividedintovesselswhich 'opened'
(DiOC7(3), noH33342)andthosewhich 'closed' (H33342, noDiOC7(3))
during the interval between stain injections. Levels of statistical
significance for non-simultaneous injections vs controls (interval = 0)
are as follows: ap<0.05; bp<0.01; cp<0.001.
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Figure 5 Effect of H33342 bolus injection (15 mg kg-' i.v.) on
the response of subcutaneous SCCVII tumour cells to 10 Gy
tumour-localised X-irradiation in restrained, unanaesthetised
male C3H/He mice. Control plating efficiency (a, mean±s.d.) is
plotted as a function of H33342 sort fraction (based on H33342
concentration); brightly stained cells are those located immed-
iately adjacent to the tumour blood supply. b, shows the surviv-
ing fraction of tumour cells after 1OGy X-rays: H33342 was
injected 20 min prior to X-rays (n = 5) (A); 20 min after X-rays
(n = 5) (A); or immediately prior to X-rays (n = 7) (0). The
responses of full oxic SCCVII tumour cells irradiated in vitro (0)
and of completely anoxic cells (killed animal; n = 5) (0) are also
shown for comparison. The average response to radiation in all
sort fractions is indicated on the left of the graph by (D) and
(-). In b error bars represent s.e.m.
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dimly stained cells distant from the blood supply. These
results are consistent with observations that H33342 tran-
siently reduced tumour perfusion; reduction in tumour blood
flow will cause impaired oxygen delivery, tumour cell
hypoxia, and a relative resistance to X-irradiation.
Discussion
The results of this study clearly indicate that the vascular
marker H33342 has vasoactive properties in the C3H/He
mouse; the stain causes a decrease in tumour blood flow and
a transient decline in mean arterial blood pressure. Several
important observations require emphasis: (1) reductions in
tumour RBC flow are dose-dependent and transient; (2)
5 mg kg-' H33342 is not significantly vasoactive; (3) flow
reductions are independent of tumour size; (4) foot tumours
show a smaller, <3 min reduction in RBC flow; (5) anaes-
thesia does not potentiate the maximum H33342-induced
flow reduction seen in foot tumours; (6) H33342 has no
significant effect on skin RBC flow.
The mechanism responsible for H33342-induced reductions
in tumour perfusion is not clear, but, based on observations
by Algire and Legallais (1951), we hypothesised that small
changes in mouse blood pressure might explain the appar-
ently selective decrease in tumour flow. Indeed, H33342
causes a transient but significant decline in mouse blood
pressure measured by direct arterial cannulation in anaes-
thetised animals. The time course of blood pressure changes
is not, however, identical to that of tumour blood flow
reductions, and therefore, perturbations in systemic pressure
probably do not entirely explain H33342-induced effects on
tumour perfusion. A direct effect of H33342 on tumour
blood vessels is possible, but no obvious reason for this
selectivity is immediately apparent.
A reduction in blood flow results in decreased tumour
oxygenation as evidenced by the increased cell survival seen if
tumours are irradiated immediately after H33342 injection.
This H33342-induced radioresistance is unlikely to be due to
a direct radioprotective effect of the stain (Smith & Ander-
son, 1984; Young & Hill, 1989) since no tumour cell radio-
protection has been observed even after in vivo administra-
tion of 400fig g' (Young & Hill, 1989), a dose 25 x that
used in the radiobiologic experiments described in this study.
H33342 has no significant influence on other physiologic/
metabolic parameters measured. Heart rate, temperature,
venous blood gases, pH, haematocrit, and oxyhaemoglobin
saturation are unchanged. Exposure of SCCVII tumour cells
in vitro to high H33342 concentrations has no effect on
relative oxygen utilisation rate of the cells.
We believe that H33342-induced reductions in tumour
blood flow are not causally related to the phenomena of
transient tumour perfusion and acute hypoxia. Several lines
of evidence support this conclusion. (1) Mean tumour cell
fluorescence increases linearly as a function of injected
H33342 dose (Chaplin & Acker, 1987) indicating that large
doses of H33342, while vasoactive, do not cause instan-
taneous tumour vessel non-perfusion and reduced stain
delivery. (2) In double-labelling experiments, approximately
equal numbers of opening vessels and closing vessels are
observed at intervals between stain injections of >5 min. If
H33342 had prolonged adverse effects on tumour perfusion,
vessel closing would be expected to predominate over vessel
opening. Vessel opening can also be demonstrated if fluores-
cent particles are used in place of DiOC7(3) as the second
vascular marker. An ideal control experiment for the double
staining method would involve injection of DiOC7(3) at some
interval before H33342, i.e. the sequence of stain injection
would be reversed. However, DiOC7(3), like H33342, causes
an abrupt transient decrease in tumour RBC flow, but this is
followed, after a brief period of recovery, by a significant
prolonged decline in perfusion (Trotter et al., 1989b). This
effect precludes the use of DiOC7(3) as a first marker in a
double staining regimen. (3) Small SCCVII tumours do not
exhibit staining mismatch indicative of transient vessel
nonperfusion (Trotter et al., 1989a) and yet such tumours
show a flow reduction after H33342 identical to that
observed in larger tumours. Thus, the degree of H33342-
induced reduction in tumour blood flow is not causally
linked to transient vessel nonperfusion. (4) H33342 injection
20 min prior to X-irradiation results in the same tumour cell
survival as when the stain is injected 20 min after irradiation.
Therefore, in support of the results obtained with laser Dop-
pler flowmetry, H33342 reductions in tumour oxygenation
are short-lived and no evidence of radiobiologic hypoxia is
observed 20 min after stain injection.
These results indicate that H33342 can be used as a marker
of functional tumour vasculature in experiments designed to
identify transient perfusion (or the resulting acute hypoxia)
provided several limitations are kept in mind. First, high
doses of H33342 should be avoided. Unfortunately, the non-
vasoactive dose (in anaesthetised mice) of 5 mg kg-' does not
provide sufficient fluorescence in tumour tissue sections to
allow accurate vessel counting using fluorescence microscopy.
A slightly higher dose might perhaps be employed when
using tumours grown in other sites (e.g. foot) and when
anaesthesia is avoided. In our laboratory, cell sorting experi-
ments are routinely performed using in vivo H33342 doses of
10mgkg-' administered to unanaesthetised mice. Second,
because H33342 reduces tumour perfusion for several
minutes, the second marker in a double staining protocol
should be injected at least 7 min after H33342, when (follow-
ing doses < 15 mg kg-') flow in back tumours has returned to
pretreatment levels. This places a limit on the temporal
resolution achievable using this technique. Similarly, H33342
should be injected at least 7 min before irradiation, or alter-
natively, after irradiation. It should be stressed that these
conclusions apply only to the SCCVII carcinoma implanted
subcutaneously in the back. Shorter intervals can likely be
safely employed using foot tumours. Other tumours types or
implantation sites may exhibit a different response to H33342
injection. It should be noted that in SCCVII foot tumours,
laser Doppler measurements were performed with a surface
probe; sampling of some skin microvasculature may explain
the less pronounced RBC flow reduction induced by H33342
in this tumours site compared to back tumours (probe placed
in direct contact with peripheral tumour tissue). Finally, the
effect of intravenous infusion of H33342 was not examined in
this study; preliminary results suggest that infusion of 10 mg
kg-' H33342 (dose required for cell sorting) over 20-30min
causes no changes in SCCVII RBC flow (unpublished obser-
vations).
In summary, H33342 has vasoactive properties; that is, the
stain causes a decrease in mean arterial blood pressure and a
transient dose-dependent decline in tumour blood flow. These
effects impose certain temporal restrictions when the stain is
employed in histological and radiobiological techniques. If
these limitations are observed, the use of H33342 does not
appear to be causally related to the phenomena of transient
perfusion and acute hypoxia.
The authors are indebted to C. Toth, C. Vikse, B. Pearson,
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recipient of a Medical Research Council (Canada) Research Fellow-
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